Hougaard C, Matthiesen T B, Rittig S, Djurhuus J C
International Enuresis Research Center, Skejby Hospital, University Hospital of Aarhus, Denmark.
Scand J Urol Nephrol Suppl. 1997;183:53-4.
The bioavailability and pharmacokinetics of desmopressin (Minirin, DDAVP) have been studied in elderly males, aged between 55 and 75 years. In a four-way randomised study, subjects received a dose of desmopressin either intravenously (2 micrograms) or orally (200 micrograms) and either at 11 am or 10 pm. Daytime and night-time urine samples were collected both with and without desmopressin treatment. Intravenous doses of desmopressin were observed to have a longer duration of action than when the dose was given orally. These differences in efficacy may be attributable to differences in the bioavailability of desmopressin after intravenous or oral treatment.
已对年龄在55至75岁之间的老年男性去氨加压素(弥凝,DDAVP)的生物利用度和药代动力学进行了研究。在一项四向随机研究中,受试者分别在上午11点或晚上10点接受静脉注射(2微克)或口服(200微克)剂量的去氨加压素。在有和没有去氨加压素治疗的情况下均采集白天和夜间的尿液样本。观察到静脉注射去氨加压素的作用持续时间比口服给药时更长。这些疗效差异可能归因于静脉注射或口服治疗后去氨加压素生物利用度的差异。